Popular terms

Erythropoietin topics
Erythropoietin
Red Blood Cell
Recombinant
Nucleic Acid
Genetically
Regulatory Sequence
Endogenous
Peptide Sequence
Carbamylated
Ischemic Stroke
Therapeutical
Intracranial
Thrombopoietin
Leukemia Inhibitory Factor
Somatostatin

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Erythropoietin patents



      

This page is updated frequently with new Erythropoietin-related patent applications.




Date/App# patent app List of recent Erythropoietin-related patents
05/12/16
20160129124 
 Derivatisation of erythropoietin (epo) patent thumbnailDerivatisation of erythropoietin (epo)
The present invention relates to a compound which is a polysaccharide derivative of epo, or of an epo like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds..
Lipoxen Technologies Limited


05/12/16
20160129123 
 Derivatisation of erythropoietin (epo) patent thumbnailDerivatisation of erythropoietin (epo)
The present invention relates to a compound which is a polysaccharide derivative of epo, or of an epo like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds..
Lipoxen Technologies Limited


05/05/16
20160123996 
 Methods and compositions for diagnosis and prognosis of renal injury and renal failure patent thumbnailMethods and compositions for diagnosis and prognosis of renal injury and renal failure
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of prostatic acid phosphatase, lactotransferrin, soluble erythropoietin receptor, von willebrand factor, soluble endothelial protein c receptor, and beta-2-glycoprotein 1 as diagnostic and prognostic biomarkers in renal injuries..
Astute Medical, Inc.


04/21/16
20160106769 
 Compounds and methods for enhancing erythropoiesis patent thumbnailCompounds and methods for enhancing erythropoiesis
Compounds and methods for enhancing erythropoiesis. The compound contains a chemical structure of the formula (i) indicated below, in which r is a glucosyl group.

04/14/16
20160101133 
 Organoids comprising isolated renal cells and use thereof patent thumbnailOrganoids comprising isolated renal cells and use thereof
Described herein are organoids comprising admixtures of selected bioactive primary renal cells and a bioactive cell population, e.g., an endothelial cell populations, e.g. Huvec cells, and methods of treating a subject in need thereof with such organoids.

03/24/16
20160083444 
 Novel feline erythropoietin receptor agonists patent thumbnailNovel feline erythropoietin receptor agonists
The present specification discloses erythropoietin receptor agonists, compositions and medicaments comprising such erythropoietin receptor agonists, methods and uses for such erythropoietin receptor agonists and compositions and medicaments, and methods and uses for erythropoietin receptor agonists and compositions and medicaments for treating an anemia.. .
Askgene Pharma, Inc.


02/25/16
20160051627 
 Long lasting drug formulations patent thumbnailLong lasting drug formulations
The present invention is directed to long-lasting therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes a therapeutic polypeptide, such as erythropoietin or interferon alpha.. .
Medgenics Medical Israel Ltd.


02/04/16
20160030525 
 Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications patent thumbnailErythropoietin and fibronectin compositions for therapeutic and cosmetic applications
A method of promoting wound healing or connective tissue reconstruction and a method of treating ischemia in a subject in need thereof are disclosed. The methods comprising topically administering to the subject about 10-30 mg per cm2 wound tissue of erythropoietin and about 100-300 mg per cm2 wound tissue of fibronectin, thereby promoting wound healing or connective tissue reconstruction or treating ischemia in the subject.
Remedor Biomed Ltd.


01/28/16
20160024166 
 Modified animal erythropoietin polypeptides and their uses patent thumbnailModified animal erythropoietin polypeptides and their uses
Modified animal erythropoietin polypeptides and uses thereof are provided.. .
Eli Lilly And Company


01/28/16
20160024165 
 Enhanced liquid formulation stability of erythropoietin alpha through purification processing patent thumbnailEnhanced liquid formulation stability of erythropoietin alpha through purification processing
A method for purifying rhuepo through the use of a multi-step filtration process which provides for a rhuepo product having superior stability and shelf-life.. .
Apotex Inc.


01/14/16
20160008386 

Composition and inducing epo-mediated haemoglobin expression and mitochondrial biogenesis in nonhaematopoietic cell


A composition for inducing erythropoietin (epo)-mediated haemoglobin (hb) expression in a nonhaematopoietic cell of a subject is provided. The composition includes a compound represented by formula (i), wherein r is a glycosyl group; and a pharmaceutical acceptable carrier..
National Yang-ming University


01/07/16
20160002603 

Selective cell therapy for the treatment of renal failure


Provided herein are isolated populations of kidney cells harvested from differentiated cells of the kidney, wherein cells have been expanded in vitro. The kidney cells may include peritubular interstitial cells of the kidney, and preferably produce erythropoietin (epo).
Wake Forest University Health Sciences


12/10/15
20150353632 

Signal biomarkers


Diagnostics relating to c-type natriuretic and erythropoietin signal peptides and fragments, and kits, uses and applications therefore.. .
Otago Innovation Limited


12/10/15
20150353489 

Erythropoietin expression promoter


The present invention provides an erythropoietin expression-enhancing agent that can cancel the suppression of erythropoietin production or promote erythropoietin production, and a therapeutic or preventive drug for anemia, a liver function-improving agent, an ischemic injury-improving agent, a renal protective agent, and an insulin secretagogue comprising the erythropoietin expression-enhancing agent. The erythropoietin expression-enhancing agent of the present invention comprises one or more compounds selected from the group consisting of compounds represented by the following general formulas (i), (ii), and (iii) and pharmaceutically acceptable salts thereof when r3 is oh..
Kanagawa Prefectural Hospital Organization Kanagawa Chilrden's Medical Center


10/29/15
20150307498 

Substituted triazolo-pyrimidine compounds for modulating cell proliferation, differentiation and survival


Disclosed herein are erythropoietin-mimetic compounds of formula i, which modulate the survival, function, or differentiation of, for example, kidney cells, neurons, erythroid cells, or other erythropoietin-responsive cells. The present invention also relates to compounds and methods that preferentially modulate cells expressing the tissue-protective erythropoietin receptor.
Stategics, Inc.


10/22/15
20150297513 

Inhalation-type pharmaceutical composition for the treatment of kidney disease and preparation method thereof


The present invention provides an inhalation-type pharmaceutical composition for kidney disease and preparation method thereof, comprising a first gas and an atomized medicine. The first gas comprises hydrogen.

09/24/15
20150265678 

Methods of treating cognitive impairment


The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (flt3) ligand, interleukin-6 (il-6), macrophage migration inhibitory factor (mif), interleukin-1 (il-1), interleukin-3 (il-3), erythropoietin (epo), vascular endothelial growth factor a (vegf-a), hypoxia-inducible transcription factor (hif-1alpha), insulin like growth factor-1 (igf-1), tumor necrosis factor (tnf), granulocyte colony-stimulating factor (g-csf), granulocyte/macrophage colony-stimulating factor (gm-csf), macrophage colony-stimulating factor (m-csf), stem cell factor (scf), darbepoetin (aranesp), and metalloproteinases, to an animal or person in need of treatment..
H. Lee Moffitt Cancer Center And Research Institute, Inc.


08/27/15
20150238556 

Neuritogenic peptides


The present invention relates to peptide compounds that are capable of stimulating neuronal differentiation, neurite outgrowth and survival of neural cells, and enhancing synaptic plasticity, learning and memory, methods of treating diseases and conditions of nervous system by administration of compositions comprising said compounds. The compounds and compositions of the invention include peptide sequences that are derived from the sequence of human erythropoietin or proteins that are homologous of human erythropoietin..
Neoloch Aps


06/18/15
20150164991 

Method and kit for evaluating and monitoring a treatment program for anemia


The present disclosure relates to methods and kits for evaluating and/or monitoring a treatment program, such as in an anemic subject or in a subject receiving treatment for anemia, including determining a presence or an amount of growth differentiation factor 15 (gdf15) and/or hepcidin in a biological sample from the subject. Further, in some embodiments, the disclosure provides methods and/or kits for treating a disorder of iron homeostasis in a subject, comprising measuring an amount of gdf15 and/or an amount of hepcidin in a sample from a subject and administering iron and/or erythropoietin (epo) to the subject if there is a measurable difference in the amount of gdf15 and/or hepcidin in the sample as compared to a reference amount..
Vanderbilt University


06/11/15
20150158924 

Derivatisation of erythropoietin (epo)


The present invention relates to a compound which is a polysaccharide derivative of epo, or of an epo like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds..
Lipoxen Technologies Limited


06/04/15
20150152156 

Tissue protective peptides and uses thereof


The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex.
Araim Pharmaceuticals, Inc.


04/30/15
20150119325 

Methods for the production of cytoprotective asialo-erythropoietin in plants and its purification from plant tissues


The present invention provides methods for the high-level production of recombinant human erythropoietin (rhuepo) derivative, asialoerythropoietin (asialo-rhuepo), in plants. The methods for producing asialo-rhuepo comprise making a plant or at least one plant cell that comprises a promoter that drives expression in a plant cell operably linked to a polynucleotide encoding a human erythropoieting fusion protein and a promoter that drives expression in a plant cell operably linked to a polynucleotide encoding n-glycosylation modification enzyme, particularly a mammalian β1,4-galactosyltransferase.
North Carolina Central University


04/30/15
20150118187 

Micro-organs providing sustained delivery of a therapeutic polypeptide and methods of use thereof


The present invention is directed to long-lasting therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a nucleic acid sequence operably linked to one or more regulatory sequences. The present invention is further directed to methods providing sustained expression of therapeutic polypeptides and prolonged therapeutic effects, such as erythropoietin and interferon..
Medgenics Medical Israel Ltd.


04/23/15
20150110743 

Long lasting drug formulations


The present invention is directed to long-lasting erythropoietin therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes erythropoietin.. .
Medgenics Medical Israel Ltd.


03/26/15
20150087695 

Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo


Oligonucleotide compounds modulate expression and/or function of erythropoietin (epo) polynucleotides and encoded products thereof. Methods for treating diseases associated with erythropoietin (epo) comprise administering one or more oligonucleotide compounds designed to inhibit the epo natural antisense transcript to patients..
Curna, Inc.


03/26/15
20150087065 

Method for generation of conditionally immortalized hematopoietic progenitor cell lines with multiple lineage potential


The present invention is a method and kits for generating a homogenous population of hematopoietic progenitor cells capable of differentiating into a hematopoietic cell lineage. Whereas the combination of homeobox-b8 protein and fms-like tyrosine kinase 3 ligand generate cells with the potential to differentiate into different myeloid and lymphoid cell types, homeobox-a7 protein and erythropoietin generate cells with the potential to differentiate into erythropoietic or thrombopoietic cell types..
St. Jude Children's Research Hospital


03/26/15
20150087060 

Method for inducing erythropoietin-producing cell


An object of the present invention is to provide a method for inducing the differentiation of erythropoietin-producing cells from human pluripotent stem cells. The above object is achieved by providing a method for inducing the differentiation of erythropoietin-producing cells from human pluripotent stem cells using a medium containing a specific growth factor and a specific compound..
Kyoto University


02/05/15
20150038403 

Compounds that bind to the erythropoietin receptor


The present invention provides mimetics of erythropoietin that bind to the erythropoietin receptor and that are suitable for use in pharmaceutical compositions. The present invention also provides methods of treatment using the mimetics of erythropoietin as well as methods of making the mimetics of erythropoietin..

01/29/15
20150031696 

Cyanoisoquinoline compounds and methods of use thereof


The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoietin-associated conditions. The cyanoisoquinoline compounds of the invention have the following structure:.
Fibrogen, Inc.


01/15/15
20150018274 

Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators


The present invention provides isolated stabilized epo-derived peptides and their mimics that protect against tissue damage in subjects having diverse forms of neural and non-neural organ system injury, pharmaceutical compositions containing the isolated stabilized epo-derived peptides, methods for treating symptoms of a disease, disorder or condition having an inflammatory or an autoimmune component in a subject in need thereof, and methods for downregulating immune mediator activity in a subject in need thereof.. .
University Of Medicine And Dentistry Of New Jersey


01/08/15
20150011574 

(2-heteroarylamino) succinic acid derivatives


The present invention provides a compound which enhances the production of erythropoietin. The present invention provides a compound represented by the formula (1) wherein r1: an aromatic hydrocarbon ring group or an aromatic heterocyclic group; r2: a hydrogen atom, an alkyl group, or a heterocycloalkyl group; r3: a hydrogen atom or an alkyl group; a: a hydrogen atom or a hydroxy group; l: —nhco— or —och2—; and x: a nitrogen atom or ═ch—..
Daiichi Sankyo Company, Limited


01/08/15
20150011552 

4-alkanoylamino-3-pyrazolone derivative


The present invention provides a compound which enhances the production of erythropoietin. The present invention provides, for example, a compound represented by the formula (1) wherein r1: -q1, -q1-x-q2, or -q1-x-q2-y-q3: a monocyclic or bicyclic aromatic heterocyclic group; q2, q3: an aromatic hydrocarbon ring group or a monocyclic aromatic heterocyclic group; x: —conh—, —conhch2—, —ch2och2—, —nhch2ch2—, or the like; y: a single bond, —o—, —(ch2)n—, or —o—(ch2)n—; m, n: an integer from 1 to 3; r2: h or an alkyl group; and r3: h, an alkoxycarbonyl group, a carboxy group, an aromatic hydrocarbon ring group, or a monocyclic aromatic heterocyclic group..
Daiichi Sankyo Company, Limited


12/25/14
20140378378 

Erythropoietin-derived peptide and use therefor


Provided are a peptide, which has an amino acid sequence of seq id no. 1 and is effective for the prevention of cell damage, and a pharmaceutical composition for preventing cell damage, the pharmaceutical composition including the peptide as an active component.

11/20/14
20140343094 

Novel nitrogen-containing heteroaryl compounds and methods of use thereof


The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.. .

10/30/14
20140323401 

Tissue protective peptides and uses thereof


The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex.

10/23/14
20140315802 

Derivatisation of erythropoietin (epo)


The present invention relates to a compound which is a polysaccharide derivative of epo, or of an epo like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds..

10/16/14
20140309407 

Derivatisation of erythropoietin (epo)


The present invention relates to a compound which is a polysaccharide derivative of epo, or of an epo like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds..

10/16/14
20140309166 

Derivatisation of erythropoietin (epo)


The present invention relates to a compound which is a polysaccharide derivative of epo, or of an epo like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds..

10/02/14
20140296318 

Novel tissue protective erythropoietin receptor (nepor) and methods of use


Methods of determining whether a patient is suitable for erythropoietin (epo) therapy, including (a) isolating a tissue sample from said patient; (b) determining the level of expression of eph-b4 in said sample; and (c) correlating a presence of eph-b4 expression to a negative physiological response to epo therapy). In addition, methods of enhancing the effectiveness of epo therapy in a patient by administering to said patient, in conjunction with epo therapy, an sirna specific for eph-b4..

10/02/14
20140296175 

Composition and inducing epo-mediated haemoglobin expression and mitochondrial biogenesis in nonhaematopoietic cell


A composition for inducing erythropoietin (epo)-mediated haemoglobin (hb) expression in a nonhaematopoietic cell of a subject is provided. The composition includes a compound represented by formula (i), wherein r is a glycosyl group; and a pharmaceutical acceptable carrier..

09/25/14
20140288172 

Erythropoietin production-promoting agent


A therapeutic and/or prophylactic agent for renal anemia comprising alas and an erythropoietin production promoter comprising alas.. .

09/11/14
20140255337 

Methods of treating cognitive impairment


The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (flt3) ligand, interleukin-6 (il-6), macrophage migration inhibitory factor (mif), interleukin-1 (il-1), interleukin-3 (il-3), erythropoietin (epo), vascular endothelial growth factor a (vegf-a), hypoxia-inducible transcription factor (hif-1alpha), insulin like growth factor-1 (igf-1), tumor necrosis factor (tnf), granulocyte colony-stimulating factor (g-csf), granulocyte/macrophage colony-stimulating factor (gm-csf), macrophage colony-stimulating factor (m-csf), stem cell factor (scf), darbepoetin (aranesp), and metalloproteinases, to an animal or person in need of treatment..

08/28/14
20140243510 

Methods for purifying erythropoietin analogs having lower isoelectric point


The present invention relates to a method for purifying an erythropoietin analog having a low isoelectric point below 4 by adding an n-linked sugar chain with high purity. In accordance with the present invention, the erythropoietin analog having an isoelectric point below 4, which is an isoform having more sialic acid residues, can be effectively purified via three-step chromatographic processes in short time at lower cost..

08/28/14
20140243324 

Use of hematopoietic growth factor mimetics


The present invention relates to uses of small molecule mimetics of hematopoietic growth factors. In particular the present invention relates to uses of small molecule mimetics of erythropoietin..

08/07/14
20140216950 

Erythropoietin receptor modified electrode and its preparation method and application


The invention discloses an erythropoietin receptor modified electrode, which is a glassy carbon electrode with erythropoietin receptor as recognition element fixed onto the electrode surface via zno sol-gel. The modified electrode can be prepared easily, and its performance is stable.

07/17/14
20140200180 

Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens


Methods for producing proteins and glycoproteins in pichia pastoris that lack detectable cross binding activity to antibodies made against host cell antigens are described. In particular, methods are described wherein recombinant pichia pastoris strains that do not display a β-mannosyltransferase 2 activity with respect to an n-glycan or o-glycan and do not display at least one activity selected from a β-mannosyltransferase 1, 3, and 4 activity to produce recombinant proteins and glycoproteins.



Erythropoietin topics: Erythropoietin, Red Blood Cell, Recombinant, Nucleic Acid, Genetically, Regulatory Sequence, Endogenous, Peptide Sequence, Carbamylated, Ischemic Stroke, Therapeutical, Intracranial, Thrombopoietin, Leukemia Inhibitory Factor, Somatostatin

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Erythropoietin for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Erythropoietin with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.3159

5139

2 - 1 - 102